Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...

Elevar Therapeutics Shares Results of Phase 2 Rivoceranib Trial in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma CHICAGO, June 06, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have...

Elevar Therapeutics Adds Drs. Honghui Zhou and David Lilienfeld as Vice Presidents Biopharmaceutical company promotes Jennifer Lee to senior vice president of clinical operations, data management and biostatistics SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) -- Elevar...

Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial Results of open-label, multicenter study will be presented during a poster session at ASCO on June 6 Rivoceranib represents a potential new treatment option for patients with R/M ACC who have...

Elevar Therapeutics Names Paul Friel Chief Commercial Officer, Michael Palucki VP of Manufacturing SALT LAKE CITY, May 23, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...